Literature DB >> 2460068

Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis.

D P Mooney1, R L Gamelli, M O'Reilly, J C Hebert.   

Abstract

Multiple immune defects have been demonstrated following thermal injury, including defective granulocyte production and function. Recombinant human granulocyte colony-stimulating factor (rhGCSF) is a regulator of the myelopoietic system. The effect of rhGCSF administration on survival and on the myelopoietic system in a murine model of Pseudomonas burn wound sepsis was investigated. Male BDF1 mice that underwent a 15% total body surface area burn injury and burn wound seeding with 1 x 10(8) Pseudomonas aeruginosa organisms demonstrated an improved mean survival time with the subcutaneous administration of 100 ng of rhGCSF twice a day. Mice that underwent a similar thermal injury and burn wound seeding with 3 x 10(7) P aeruginosa organisms demonstrated an augmented myelopoietic response through the administration of rhGCSF, as represented by significantly increased white blood cell count, neutrophil count, splenic weight, femoral marrow cellularity, and femoral marrow granulocyte-macrophage colony-forming cell count. Myelopoietic augmentation through rhGCSF administration may serve to decrease the morbidity of septic events following thermal injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2460068     DOI: 10.1001/archsurg.1988.01400350067010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

1.  Colony-Stimulating Factors in the Therapeutic Approach to Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against Pseudomonas aeruginosa infections in mice.

Authors:  H Yasuda; Y Ajiki; T Shimozato; M Kasahara; H Kawada; M Iwata; K Shimizu
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

Review 3.  The role of mediators in the response to thermal injury.

Authors:  Y K Youn; C LaLonde; R Demling
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

4.  Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model.

Authors:  U Frank; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Activation of neutrophil function by recombinant human granulocyte colony-stimulating factor improves the survival of rats with peritonitis.

Authors:  H Ishikura; Y Uedono; K Yamagami; T Arai; N Takeyama; T Tanaka
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

6.  Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits.

Authors:  C Ostergaard; T Benfield; B Gesser; A Kharazmi; N Frimodt-Møller; F Espersen; J D Lundgren
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

7.  Effects of granulocyte colony-stimulating factor on bacterial translocation due to burn wound sepsis.

Authors:  O Yalçin; G Soybir; F Köksoy; H Köse; R Oztürk; B Cokneşeli
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

8.  Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice.

Authors:  T Lazard; C Perronne; Y Cohen; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Mechanisms of neutropenia involving myeloid maturation arrest in burn sepsis.

Authors:  M Shoup; J M Weisenberger; J L Wang; J M Pyle; R L Gamelli; R Shankar
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  Biological response modifiers and infectious diseases: actual and potential therapeutic agents.

Authors:  J J Rusthoven
Journal:  Int J Antimicrob Agents       Date:  1994       Impact factor: 5.283

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.